Vanda Pharmaceuticals shares rose nearly 5% pre-market after the FDA accepted its Biologics License Application for Imsidolimab to treat Generalized Pustular Psoriasis. Clinical data showed over half of patients achieved clear skin by week four. The drug addresses a rare, life-threatening disorder, boosting retail sentiment to extremely bullish.